Compare OPLN & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | BLLN |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | 4800 | 713 |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | N/A | N/A |
| Metric | OPLN | BLLN |
|---|---|---|
| Price | $37.86 | $103.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $32.00 | ★ $126.71 |
| AVG Volume (30 Days) | ★ 895.7K | 710.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.43 | $46.29 |
| Revenue Next Year | $6.80 | $30.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.81 | $61.96 |
| 52 Week High | $39.49 | $138.70 |
| Indicator | OPLN | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 59.87 |
| Support Level | $36.17 | $79.07 |
| Resistance Level | $38.94 | $108.50 |
| Average True Range (ATR) | 1.17 | 7.70 |
| MACD | -0.10 | 0.21 |
| Stochastic Oscillator | 57.23 | 77.49 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.